Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Health and Medical Research Fund | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The objective of this prospective, randomized controlled study was to evaluate the effectiveness of this NCH gel in the prevention of IUA development as assessed by hysteroscopy after USG-MVA, in the treatment for first-trimester miscarriage.
There is limited data to evaluate the incidence of IUA after using this NCH gel in patients undergoing surgical evacuation via USG-MVA for the treatment of first-trimester miscarriage. Previous RCT showed a significant reduction in IUA with the use of NCH gel, with IUA detected in only 9.5% of patients with NCH gel applied compared to 24.1% in the control group. However, the group did not involve patients undergoing surgical evacuation by USG-MVA.
Therefore, the objective of this prospective, randomized controlled study was to evaluate the effectiveness of this NCH gel in the prevention of IUA development as assessed by hysteroscopy after USG-MVA, in the treatment of first-trimester miscarriage.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group (Group A): NCH gel after USG-MVA | Experimental | In the intervention group (Group A), a 15 cm sterile delivery cannula will be inserted through the internal os and a syringe of NCH gel (5ml) will be applied to the uterine cavity after cleansing the cervix with an antiseptic solution. |
|
| Controlled group (Group B): No NCH gel after USG-MVA | No Intervention | In the control group (Group B), as the patient is conscious during the procedure, an empty 5ml syringe will be inserted into the internal os and held for 1 minute as a sham procedure. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MateRegen® gel (BioRegen) | Device | Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of IUA | To determine the incidence of IUA or after USG-MVA for the treatment of first-trimester miscarriage in both intervention and control groups. | 8-12 weeks after MVA |
| Measure | Description | Time Frame |
|---|---|---|
| Severity and extent of the intrauterine adhesions as assessed by the AFS adhesion score | To study the severity and extent of the intrauterine adhesions as assessed by the AFS adhesion score in both groups of patients. The American Fertility Society's (AFS) classification of intrauterine adhesions: Stage I (mild) with score 1-4, Stage II (moderate) with score 5-8, Stage III (severe) with score 9-12 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Elaine NG | Contact | 35052745 | elaineng@cuhk.edu.hk | |
| Stacey Wong, Bsc | Contact | 35051764 | staceywong@cuhk.edu.hk |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Chinese University of Hong Kong | Recruiting | Hong Kong | Hong Kong |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006175 | Gynatresia |
| D000022 | Abortion, Spontaneous |
| ID | Term |
|---|---|
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 8-12 weeks after MVA |
| Severity and extent of the intrauterine adhesions as assessed by the ESGE adhesion score | To study the severity and extent of the intrauterine adhesions as assessed by the European Society of Gynaecological Endoscopy (ESGE) adhesion score in both groups of patients. It includes grades I and II as mild adhesion, grade III as moderate adhesion, grades IV and V as severe adhesion | 8-12 weeks after MVA |
| Complications or side effects with the NCH gel. | To examine the rate of complications or side effects with the NCH gel. | 8-12 weeks after MVA |
| Subsequent menstrual frequency | To assess the subsequent menstrual frequency in both groups of patients. Frequency - average 28 days <24 days Frequent, >38 days Infrequent Frequency - average 28 days <24 days Frequent, >38 days Infrequent | 8-12 weeks after MVA |
| Subsequent reproductive outcome | To assess the rate of pregnancy in both groups of patients | 8-12 weeks after MVA |
| D000091662 | Genital Diseases |
| D011248 | Pregnancy Complications |